DEF: Mirion Technologies Reports Record Orders, Strong 2025 Growth

Mirion Technologies announced record orders and double-digit organic revenue growth in key markets for 2025, driven by strategic acquisitions and strong market tailwinds.

Summary

• Mirion Technologies' 2026 Annual Stockholders' Meeting will be held virtually on May 13, 2026, at 10:00 a.m. Eastern Time.
• The company booked a record $1+ billion in orders in 2025, representing a 26% increase compared to 2024.
• Organic revenue from both Nuclear Power and Nuclear Medicine end-markets grew double-digits in 2025.
• Mirion acquired Certrec in July 2025 and Paragon Energy Solutions in December 2025, significantly increasing its nuclear power exposure.
• Pro-forma commercial nuclear power revenue now constitutes approximately 47% of Mirion's total revenue, up from 37% prior to these acquisitions.
• The principal business of the Annual Meeting includes the election of eight directors, ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and a non-binding advisory vote on executive compensation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, reflecting strong operational and financial performance, strategic market expansion through acquisitions, and robust corporate governance enhancements. The significant turnaround in net income and record orders underscore a strong growth trajectory.

Positives

• Record $1+ billion in orders in 2025, a 26% increase over 2024, indicating strong demand and market penetration.
• Double-digit organic revenue growth in both Nuclear Power and Nuclear Medicine end-markets for 2025.
• Successful strategic acquisitions of Certrec and Paragon Energy Solutions in 2025, enhancing nuclear power market exposure and capabilities.
• Significant increase in pro-forma commercial nuclear power revenue to 47% of total revenue, up from 37%, aligning with strategic goals.
• Turnaround in GAAP Net Income to $29.8 million in 2025 from a net loss of ($36.6) million in 2024.
• Adjusted EBITDA increased by 11.9% to $227.9 million in 2025 compared to $203.6 million in 2024.
• Enterprise Adjusted Free Cash Flow of $121.0 million significantly exceeded the target of $100.0 million and the maximum of $120.0 million for 2025.
• 2022 Performance Stock Units (PSUs) vested at 191.20% of target, reflecting strong achievement of performance goals (Relative TSR 182.40%, Organic Revenue Growth 200%).

Negatives

• Enterprise Adjusted Organic Revenue Growth of 3.9% for 2025 was below the target of 6.4% and the threshold of 4.4% for STIP payout, resulting in 0% payout for this metric.
• Nuclear & Safety Group Adjusted Organic Revenue Growth of 4.4% for 2025 was below the target of 7.6% and the threshold of 5.5% for STIP payout, resulting in 0% payout for this metric.

Risks

• The Board provides oversight of the company's Enterprise Risk Management (ERM) framework and processes, including risk identification, assessment, ownership, mitigation planning, execution, escalation, and reporting.
• The Audit Committee assists the Board in overseeing risk management, including financial reporting integrity, compliance, legal and regulatory matters, internal controls, and ERM program governance.
• The company operates in complex, highly regulated environments (nuclear power and medical technologies), requiring robust oversight of regulatory compliance and risk mitigation.
• Cybersecurity and data security risks are a focus, with the Board overseeing the company's efforts to protect customer, employee, vendor, and non-public company information.
• Supply chain risks are considered, with directors providing insight into operational resilience and risk management to ensure continuity.

Future Outlook

Mirion Technologies anticipates continued momentum across the nuclear power and cancer care end-markets, driven by increasing demand for power to support data center and artificial intelligence infrastructure, an aging global population, and elevating standards of care in developing markets. Recent acquisitions of Certrec and Paragon Energy Solutions are expected to further enhance nuclear power exposure and create opportunities across the full lifecycle of nuclear reactors, including advanced and small modular reactors. The company's long-term incentive plans are tied to performance goals through December 31, 2027, reflecting a focus on sustained growth and profitability.

Management Comments

• "Momentum continues to build broadly across the nuclear power and cancer care end-markets."
• "In the nuclear power market, power availability is becoming increasingly critical to support data center and artificial intelligence infrastructure."
• "In 2025 we booked a record $1+ billion of orders. This reflects a 26% increase compared to 2024, driven by both the tailwinds in our key vertical markets and our augmented capabilities."
• "Notably, 2025 organic revenue from both our Nuclear Power and Nuclear Medicine end-markets grew double-digits."
• "Pro-forma commercial nuclear power revenue is now approximately 47% of Mirion revenue, up significantly from 37% prior to these acquisitions."
• "We encourage you to cast your vote on the items up for vote at our 2026 Annual Stockholders Meeting, which are laid out in the accompanying proxy statement along with voting instructions."

Industry Context

StockSavvy.ai notes that Mirion Technologies is strategically positioned within two high-growth sectors: nuclear power and cancer care. The company's emphasis on nuclear power aligns with broader industry trends of increasing energy demand, particularly from data centers and AI infrastructure, and the renewed interest in nuclear energy, including advanced and small modular reactors, for reliable and clean power. In cancer care, Mirion benefits from demographic shifts like an aging global population and rising healthcare standards in emerging markets, driving demand for advanced medical technologies. The recent acquisitions of Certrec and Paragon Energy Solutions demonstrate a clear strategy to capitalize on these tailwinds and expand market share in critical infrastructure and healthcare segments.

Comparison to Industry Standards

• Mirion Technologies uses the Russell 2000 Industrials Index as a comparator group for measuring Relative Total Shareholder Return (TSR) in its Performance Stock Unit (PSU) awards, indicating a benchmark against a broad set of industrial companies.
• The company's 2025 Adjusted EBITDA growth of 11.9% and GAAP Net Income turnaround from a loss to a profit suggest strong operational performance relative to its prior year, but no direct comparison to specific industry peers' 2025 results is provided in the filing.
• The 2022 PSUs achieved a 191.20% payout, with Relative TSR at 182.40% and organic revenue growth at 200%, indicating superior performance against internal targets and the Russell 2000 Industrials Index for that specific performance period.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into indemnification agreements with its directors and executive officers.
• The company is party to an insurance policy that insures its directors and executive officers against certain liabilities.
• The Audit Committee has adopted a formal Related Party Transaction Policy for reviewing and approving or ratifying transactions exceeding $120,000 where a related party has a direct or indirect material interest.

Stakeholder Impact

• Shareholders: Benefit from strong financial performance (record orders, double-digit organic growth, net income turnaround), strategic acquisitions, and enhanced corporate governance practices aimed at long-term value creation.
• Employees: Benefit from a commitment to being an employer of choice, competitive compensation and benefits, professional development opportunities, a Volunteer Time Off Program, Parental Leave Policy, and global mental health resources. Executive compensation is tied to performance, aligning leadership with company success.
• Customers: Benefit from augmented capabilities and strategic focus on nuclear power and cancer care, leading to improved products and services, particularly in critical infrastructure and life-saving medical procedures.
• Suppliers/Vendors: Subject to a Supplier Code of Conduct, which outlines expectations for socially and environmentally friendly operations, human rights, and ethical business practices, potentially impacting their operational standards.
• Regulatory Authorities: The company operates in highly regulated environments and has enhanced its corporate governance, compliance, and risk oversight, including cybersecurity, demonstrating a commitment to meeting regulatory standards.

Next Steps

• Stockholders to vote on the election of directors, ratification of Deloitte & Touche LLP as independent auditor, and a non-binding advisory vote on executive compensation at the Annual Meeting on May 13, 2026.
• Management to continue executing on strategic priorities in nuclear power and cancer care, leveraging recent acquisitions.
• Ongoing monitoring and reporting of Enterprise Risk Management (ERM) framework and cybersecurity risks to the Board and Audit Committee.
• Stockholders wishing to present proposals for the 2027 annual meeting must submit them by December 2, 2026 (Rule 14a-8) or between December 14, 2026, and January 13, 2027 (Bylaws).

Key Dates

Recommendation

The filing presents a highly positive outlook and strong financial performance for Mirion Technologies. Record orders, double-digit organic revenue growth in key segments, and a significant turnaround from a net loss to a net profit in 2025 demonstrate robust operational execution and market momentum. Strategic acquisitions further strengthen its position in high-growth nuclear power and cancer care markets. While some STIP metrics were missed, the overall financial trajectory and long-term incentive payouts (2022 PSUs at 191.20% of target) indicate strong value creation. The enhanced corporate governance framework also provides a solid foundation. These factors collectively suggest a strong investment opportunity.

Keywords

Nuclear Power, Cancer Care, SEC Filing, Proxy Statement, MIRION TECHNOLOGIES, M&A, Acquisitions, Certrec, Paragon Energy Solutions, Organic Revenue Growth, Adjusted EBITDA, Corporate Governance, Executive Compensation, Risk Management, Cybersecurity, Shareholder Meeting